Stroke. Safety. Strategy: The Factor XIa Revolution 🚀🧠

  A quiet shift, yet a profound one. 🧠   The OCEANIC-STROKE trial introduces asundexian, a Factor XIa inhibitor that lowers recurrent ischemic stroke risk (HR 0.74) without increasing major bleeding—a long-sought balance in antithrombotic therapy.   For decades, we traded efficacy for safety. Now, we may finally have both. ⚖️   The implications extend beyond stroke—to a broader rethinking of thrombosis itself: can we uncouple clot from bleed?   This study suggests we can.   #StrokePrevention #Cardiology #Neurology #ClinicalTrials #Anticoagulation #PrecisionMedicine